MedPath

KOELIS

🇫🇷France
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (100.0%)

Efficacy Assessment of a Novel 3D Cartography-based Targeted Focal Microwave Therapy in Men With Localized Intermediate-risk Prostate Cancer

Not Applicable
Conditions
Prostate Cancer
First Posted Date
2020-10-09
Last Posted Date
2021-08-06
Lead Sponsor
Koelis
Target Recruit Count
65
Registration Number
NCT04582656
Locations
🇧🇪

Institut Jules Bordet, Brussels, Belgium

🇫🇷

Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

🇫🇷

American Hospital of Paris, Neuilly-sur-Seine, France

and more 4 locations

News

Koelis and Bot Image Partner to Enhance Prostate Cancer Detection with AI-Powered Fusion Biopsy Technology

Koelis has announced a strategic partnership with Bot Image to integrate ProstatID™, an FDA-cleared AI-based lesion detection software, with their Trinity® MRI-fusion guidance system for improved prostate cancer diagnostics.

VIOLETTE Trial Shows Promise for Precise Microwave Ablation in Prostate Cancer

Interim results from the VIOLETTE trial indicate that organ-based tracking fusion (OBT-Fusion) technology allows for precise planning in targeted microwave ablation of prostate cancer.

KOELIS Announces Positive Interim Results from VIOLETTE Trial on Targeted Microwave Ablation for Prostate Cancer

The VIOLETTE trial, a multicenter Phase II study, evaluates KOELIS' OBT-Fusion technology for targeted microwave ablation (TMA) in prostate cancer.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.